Login to Your Account



Other News To Note


Thursday, January 12, 2012
• OctoPlus NV, of Leiden, the Netherlands, signed an agreement with a major pharmaceutical company based in the U.S. to explore the feasibility of a controlled-release formulation of a compound for delivery to the joints. Under the agreement, OctoPlus will develop the formulation using its PolyActive technology. If successful, there is potential for a development and manufacturing license agreement.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription